Prenylation of HDAg and Antiviral Drug Development

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 307)


Hepatitis delta virus (HDV) is an important cause of acute and chronic liver disease. Current medical therapies are unable to effectively eradicate HDV infections. Research into the molecular virology of the HDV life cycle has revealed a fascinating collection of biology. These insights are now beginning to be translated into new potential treatment strategies. For example, an essential step in the virus assembly process involves the post-translational lipid modification of a specific HDV protein, namely prenylation of large delta antigen. Preventing prenylation abolishes virus particle formation. Drugs capable of specifically inhibiting prenylation have been developed for use in humans. These agents represent a new class of antiviral agents, with HDV as a first target. Here, a brief review of the HDV life cycle emphasizing the role of prenylation is presented along with implications for drug development and therapy.


Hepatitis Delta Virus Hepatitis Delta Virus Infection Delta Antigen Chronic Delta Hepatitis Antiviral Drug Development 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, Young SG (2004) Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest 539–550Google Scholar
  2. Bordier BB, Marion PL, Ohashi K, Kay MA, Greenberg HB, Casey JL, Glenn JS (2002) A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J. Virol 10465–10472Google Scholar
  3. Bordier BB, Ohkanda J, Liu P, Kim SY, Salazar FH, Marion PL, Meuse L, Ohashi K, Kay MA, Casey JL (2003) In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus (HDV). J Clin Invest 407–414Google Scholar
  4. Casey JL (1996) Hepatitis delta virus. Genetics and Pathogenesis. Clinics Lab Med 451–464Google Scholar
  5. Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL (1993) A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci USA 9016–9020Google Scholar
  6. Casey PJ (1995) Protein lipidation in cell signaling. Science 221–225Google Scholar
  7. Chang F-L, Chen P-J, Tu S-J, Wang C-J, Chen D-S (1991) The large form of hepatitis d antigen is crucial for assembly of hepatitis D virus. Proc Natl Acad Sci USA 8490–8494Google Scholar
  8. Chang J, Sigal LJ, Lerro A, Taylor J (2001) Replication of the human hepatitis delta virus genome Is initiated in mouse hepatocytes following intravenous injection of naked DNA or RNA sequences. J Virol 3469–3473Google Scholar
  9. Chang M-F, Chang SC, Chang C-I, Wu K, Kang H-Y (1992) Nuclear localization signals, but not putative leucine zipper motifs, are essential for nuclear transport of hepatitis delta antigen. J Virol 6019–6027Google Scholar
  10. Chao M, Hsieh S-Y, Taylor J (1990) Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. J Virol 5066–5069Google Scholar
  11. Chen P-J, Chang F-L, Wang C-J, Lin C-J, Sung S-Y, Chen D-S (1992) Functional study of hepatitis delta virus large antigen in packaging and replication inhibition: Role of the amino-terminal leucine zipper. J Virol 2853–2859Google Scholar
  12. Chou H-C, Hsieh T-Y, Sheu G-T, Lai MMC (1998) Hepatitis delta antigen mediates the nuclear import of hepatitis delta virus RNA. J Virol 3684–3690Google Scholar
  13. Cirelli R, Herne K, McCrary M, Lee P, Tyring SK (1996) Famciclovir: review of clinical efficacy and safety. Antiviral Res 141–151Google Scholar
  14. Dalton MB, Fantle KS, Bechtold HA, DeMaio L, Evans RM, Krystosek A, Sinensky M (1995) The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21ras but does not affect their function or localization. Cancer Res 3295–3304Google Scholar
  15. Elazar M, Glenn JS (2005) Confronting new and old antiviral threats: broad spectrum potential of prenylation inhibitors. In: Torrence PF, ed. Antiviral drug discovery for emerging diseases and bioterrorism threats: John Wiley & Sons, Inc. pp 249–261Google Scholar
  16. Farassati F, Yang AD, Lee PW (2001) Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 745–750Google Scholar
  17. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, Gibo Y, Caruso L, Scaccabarozzi S, Criscuolo D and others (1994) Treatment of chronic hepatitis D with interferon alfa-2a. New Engl J Med 88–94Google Scholar
  18. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, Serra G, Lai ME, Loy M, Caruso L, et al. (2004) Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 1740–1749Google Scholar
  19. Farnsworth CC, Gelb MH, Glomset JA (1990) Identification of geranylgeranyl-modified proteins in HeLa cells. Science 320–322Google Scholar
  20. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA (1989) Human lamin B contains a farnesylated cysteine residue. J Biol Chem 20422–20429Google Scholar
  21. Gerin JL, Casey JL, Purcell RH (2001) Hepatitis delta virus. In: Howley PM, ed. Fields virology. Philadelphia: Lippincot & Wilkins. pp 3037–3050Google Scholar
  22. Glenn JS (1999) Shutting the door on hepatitis delta virus (HDV): Sensitivity to prenylation inhibition prompts new therapeutic strategy. Viral Hepatitis Reviews 5:13–26Google Scholar
  23. Glenn JS, Marsters Jr. JC, Greenberg HB (1998) Use of a prenylation inhibitor as a novel antiviral agent. J Virol 9303–9306Google Scholar
  24. Glenn JS, Watson JA, Havel CM, White JM (1992) Identification of a prenylation site in delta virus large antigen. Science 1331–1333Google Scholar
  25. Glenn JS, White JM (1991) Trans-dominant inhibition of human hepatitis delta virus genome replication. J Virol 2357–2361Google Scholar
  26. Gower TL, Graham BS (2001) Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother 1231–1237Google Scholar
  27. Hancock JF, Cadwallader K, Marshall CJ (1991) Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J 641–646Google Scholar
  28. Hancock JF, Magee AI, Childs JE, Marshall CJ (1989) All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1167–1177Google Scholar
  29. Hoffman GR, Nassar N, Cerione RA (2000) Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI. Cell 345–356Google Scholar
  30. Hoofnagle JH (1989) Type D (delta) hepatitis. JAMA 1321–1325Google Scholar
  31. Hwang SB, Lai MMC (1993) Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen. J Virol 7659–7662Google Scholar
  32. Hwang SB, Lee C-Z, Lai MMC (1992) Hepatitis delta antigen expressed by recombinant baculoviruses: Comparison of biochemical properties and post-translational modifications between the large and small forms. Virology 413–422Google Scholar
  33. Jabbour E, Kantarjian H, Cortes J (2004) Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma 2187–2195Google Scholar
  34. James GL, Brown MS, Cobb MH, Goldstein JL (1994) Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells. J Biol Chem 27705–27714Google Scholar
  35. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JCJ (1993) Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 1937–1942Google Scholar
  36. Kapadia SB, Chisari FV (2005) Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2561–2566Google Scholar
  37. Kim E, Ambroziak P, Otto JC, Taylor B, Ashby M, Shannon K, Casey PJ, Young SG (1999) Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J Biol Chem 8383–8390Google Scholar
  38. Lau D, Doo E, Park Y, Kleiner D, Schmid P, Kuhns M, Hoofnagle J (1999) Lamivudine for chronic delta hepatitis. Hepatology 546–549Google Scholar
  39. Lazinski DW, Taylor JM (1993) Relating structure to function in the hepatitis delta virus antigen. J Virol 2672–2680Google Scholar
  40. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, al. e (1999) Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. Cancer Chemother Pharmacol 50–58Google Scholar
  41. Maltese WA (1990) Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 3319–3328Google Scholar
  42. Mazieres J, Pradines A, Favre G (2004) Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Lett 159–167Google Scholar
  43. McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, McNab D, Perry LJ, Scott JE, Taylor P (1988) The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol 1531–1574Google Scholar
  44. Novick P, Brennwald P (1993) Friends and family: The role of the Rab GTPases in vesicular traffic. Cell 597–601Google Scholar
  45. Otto JC, Casey PJ (1996) The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells. J Biol Chem 4569–4572Google Scholar
  46. Parish CA, Rando RR (1996) Isoprenylation/methylation of proteins enhances membrane association by a hydrophobic mechanism. Biochemistry 8473–8477Google Scholar
  47. Pereira-Leal JB, Seabra MC (2001) Evolution of the Rab family of small GTP-binding proteins. J Mol Biol 889–901Google Scholar
  48. Pfeffer S, Aivazian D (2004) Targeting Rab GTPases to distinct membrane compartments. Nat Rev Mol Cell Biol 886–896Google Scholar
  49. Pullarkat RK, Morris GN (1997) Farnesylation of Batten disease CLN3 protein. Neuropediatrics 42–44Google Scholar
  50. Radjef N, Gordien E, Ivaniushina V, Gault E, Anais P, Drugan T, Trinchet JC, Roulot D, Tamby M, Milinkovitch MC and others (2004) Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2537–2544Google Scholar
  51. Rizzetto M, Ponzetto A, Forzani I (1991) Epidemiology of hepatitis delta virus: Overview. In: Rizetto M, editor. The hepatitis delta virus. New York: Wiley-Liss Inc. pp 1–20Google Scholar
  52. Rowinsky EK, Windle JJ, Von Hoff DD (1999) Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 3631–3652Google Scholar
  53. Ryu W-S, Bayer M, Taylor J (1992) Assembly of hepatitis delta virus particles. J Virol 2310–2315Google Scholar
  54. Samuel D, Zignego A-L, Reynes M, Feray C, Arulnaden JL, David M-F, Gigou M, Bismuth A, Mathieu D, Gentilini P and others (1995) Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology pp 333–339Google Scholar
  55. Sato S, Cornillez-Ty C, Lazinski DW (2004) By inhibiting replication, the large hepatitis delta antigen can indirectly regulate amber/W editing and its own expression. J Virol 8120–8134Google Scholar
  56. Sebti SM, Hamilton AD (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 6584–6593Google Scholar
  57. Sharma S, Kemeny N, Kelsen DP, Ilson D, O’Reilly E, Zaknoen S, Baum C, Statkevich P, Hollywood E, Zhu Y, et al. (2002) A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 1067–1071Google Scholar
  58. Shih KN, Lo SJ (2001) The HDV large-delta antigen fused with GFP remains functional and provides for studying its dynamic distribution. Virology 138–152Google Scholar
  59. Silvius JR, l’Heureux F (1994) Fluorimetric evaluation of the affinities of isoprenylated peptides for lipid bilayers. Biochemistry 3014–3022Google Scholar
  60. Sinensky M, Beck LA, Leonard S, Evans R (1990) Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 19937–19941Google Scholar
  61. Sun J, Qian Y, Hamilton AD, Sebti SM (1995) Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 4243–4247Google Scholar
  62. Sureau C, Guerra B, Lanford RE (1993) Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion. J Virol 366–372Google Scholar
  63. Sureau C, Moriarty AM, Thornton GB, Lanford RE (1992) Production of infectious hepatitis delta virus in vitro and neutralization with antibodies directed against hepatitis B virus pre-S antigens. J Virol 1241–1245Google Scholar
  64. Wei Y, Ganem D (1998) Activation of heterologous gene expression by the large isoform of hepatitis delta virus. J Virol 2089–2096Google Scholar
  65. Winter-Vann AM, Baron RA, Wong W, dela Cruz J, York JD, Gooden DM, Bergo MO, Young SG, Toone EJ, Casey PJ (2005) A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci USA 4336–4341Google Scholar
  66. Winter-Vann AM, Casey PJ (2005) Opinion: Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 405–412Google Scholar
  67. Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, de Man RA (2000) Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 428–434Google Scholar
  68. Xia Y-P, Yey C, Ou J-S, Lai MMC (1992) Characterization of nuclear targeting signal of hepatitis delta antigen: Nuclear transport as a protein complex. J Virol 914–921Google Scholar
  69. Yamane HK, Farnsworth CC, Xie H, Howald W, Fung BK-K, Clarke S, Gelb MH, Glomset JA (1990) Brain G protein g subunits contain an all-trans-geranylgeranylcysteine methyl ester at their carboxyl termini. Proc Natl Acad Sci USA 5868–5872Google Scholar
  70. Ye J, Wang C, Sumpter R, Jr., Brown MS, Goldstein JL, Gale M, Jr. (2003) Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 15865–15870Google Scholar
  71. Yurdaydin C, Bozkaya H, Gurel S, Tillmann HL, Aslan N, Okcu-Heper A, Erden E, Yalcin K, Iliman N, Uzunalimoglu O and others (2002) Famciclovir treatment of chronic delta hepatitis. J Hepatol 266–271Google Scholar
  72. Zhang FL, Casey PJ (1996) Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 241–269Google Scholar
  73. Zignego AL, Samuel D, Gentilini P, Bismuth H (1993) Patterns and mechanisms of hepatitis B/hepatitis D reinfection after liver transplantation. Arch Virol Suppl 281–289Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyStanford University School of MedicinePalo AltoUSA

Personalised recommendations